Over 14.2 billion! AstraZenda has become a blockbuster cooperation

發(fā)布時(shí)間： 2023-06-15 閱讀：597次

分享

AstraZeneca has entered into an exciting collaboration, exclusive option and license agreement with Quell Therapeutics to develop multiple engineered T-regulator (Treg) cell therapies that have the potential to be curative in Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD) indications.

Tregs have functions such as inhibiting the body's immune response, actively tolerating their own antigens, participating in tumor immune escape, and anti-inflammatory. They can block anti-tumor immune responses through various mechanisms, while also possessing the function of suppressing excessive immune responses that cause inflammation.

Quell will receive $85 million upfront from AstraZeneca, which comprises a predominant cash payment and an equity investment. Quell is also eligible to receive over $2 billion for further development and commercialisation milestones, if successful, plus tiered royalties. 

In addition, Quell retains an option, which can be exercised either after approval of an Investigational New Drug (IND) application or at the end of the Phase I/II clinical study, to co-develop Treg cell therapies from the T1D programme with AstraZeneca in the United States in exchange for additional milestone payments and increased royalties on US net sales.

According to incomplete statistics, this is also a purchase of AstraZeneca with the largest amount of capital this year.

AstraZeneca said that it hoped to expand its next-generation treatment tools through Quell cooperation and explore the untapped potential of Treg Cell therapy in terms of autoimmune indications.